Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

[A Case of Laparoscopic Hepatectomy and Combined Resection of Lymph Nodes and Ureter for Liver Metastasis after Colorectal Cancer Surgery, with Local Lymph Node Recurrence and Bilateral Hydronephrosis].

Sato T, Sakai H, Goto Y, Kojima S, Nomura Y, Nakayama G, Hirakawa Y, Mikagi K, Kawahara R, Ishikawa H, Hisaka T, Yasunaga M, Tanaka H, Akagi Y, Okuda K.

Gan To Kagaku Ryoho. 2019 Apr;46(4):751-753. Japanese.

PMID:
31164524
2.

Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens.

Sonohara F, Yamada S, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Eur J Surg Oncol. 2019 May 22. pii: S0748-7983(19)30457-3. doi: 10.1016/j.ejso.2019.05.019. [Epub ahead of print]

PMID:
31147087
3.

Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer.

Kato Y, Yamada S, Tashiro M, Sonohara F, Takami H, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y.

HPB (Oxford). 2019 Feb 14. pii: S1365-182X(19)30067-X. doi: 10.1016/j.hpb.2019.01.012. [Epub ahead of print]

PMID:
30773450
4.

Acute iliac arterial thrombosis during laparoscopic abdominoperineal resection.

Sahara K, Ishibe A, Yabuno T, Kondo H, Nakayama G, Yasuda S, Nishida T, Watanabe J, Uranaka Y, Akiyama H, Sugita A, Endo I.

J Surg Case Rep. 2019 Feb 5;2019(2):rjz020. doi: 10.1093/jscr/rjz020. eCollection 2019 Feb.

5.

Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma.

Sonohara F, Yamada S, Tanaka N, Suenaga M, Takami H, Hayashi M, Niwa Y, Sugimoto H, Hattori N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Ann Gastroenterol Surg. 2018 Sep 27;3(1):65-74. doi: 10.1002/ags3.12212. eCollection 2019 Jan.

6.

Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival.

Miwa T, Kanda M, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y.

Ann Surg Oncol. 2019 May;26(5):1535-1543. doi: 10.1245/s10434-019-07166-5. Epub 2019 Jan 23.

PMID:
30673899
7.

Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer.

Uno Y, Kanda M, Miwa T, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2019 Mar;26(3):836-844. doi: 10.1245/s10434-018-07149-y. Epub 2019 Jan 7.

PMID:
30617870
8.

Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.

Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

J Transl Med. 2019 Jan 3;17(1):1. doi: 10.1186/s12967-018-1762-6.

9.

Transanal extended rectal surgery with lateral pelvic lymph node dissection.

Aiba T, Uehara K, Mukai T, Hattori N, Nakayama G, Nagino M.

Tech Coloproctol. 2018 Nov;22(11):893-894. doi: 10.1007/s10151-018-1891-1. Epub 2018 Nov 27. No abstract available.

PMID:
30483903
10.

Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.

Tomida A, Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Okada Y, Kurumiya Y, Nakayama G, Nakamura M, Aiba T, Nagino M; Of the Nagoya Surgical Oncology Group.

Int J Clin Oncol. 2019 Apr;24(4):403-410. doi: 10.1007/s10147-018-1372-6. Epub 2018 Nov 23.

PMID:
30471067
11.

Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification.

Morimoto D, Yamada S, Murotani K, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tashiro M, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Pancreas. 2018 Nov/Dec;47(10):1350-1356. doi: 10.1097/MPA.0000000000001186.

PMID:
30286011
12.

Copine 5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma.

Umeda S, Kanda M, Koike M, Tanaka H, Miwa T, Tanaka C, Kobayashi D, Suenaga M, Hayashi M, Yamada S, Nakayama G, Kodera Y.

Oncol Rep. 2018 Dec;40(6):3772-3780. doi: 10.3892/or.2018.6742. Epub 2018 Sep 27.

PMID:
30272363
13.

Expression of sushi domain containing two reflects the malignant potential of gastric cancer.

Umeda S, Kanda M, Miwa T, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Cancer Med. 2018 Oct;7(10):5194-5204. doi: 10.1002/cam4.1793. Epub 2018 Sep 27.

14.

Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer.

Tashiro M, Yamada S, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Ann Surg Oncol. 2018 Oct;25(11):3365-3371. doi: 10.1245/s10434-018-6699-8. Epub 2018 Aug 10.

PMID:
30097739
15.

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).

Nakayama G, Mitsuma A, Sunagawa Y, Ishigure K, Yokoyama H, Matsui T, Nakayama H, Nakata K, Ishiyama A, Asada T, Umeda S, Ezaka K, Hattori N, Takami H, Kobayashi D, Tanaka C, Kanda M, Yamada S, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y.

Oncologist. 2018 Aug;23(8):919-927. doi: 10.1634/theoncologist.2017-0640. Epub 2018 Jul 26.

PMID:
30049885
16.

Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms.

Yamada S, Fujii T, Hirakawa A, Takami H, Suenaga M, Hayashi M, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Pancreas. 2018 Sep;47(8):974-979. doi: 10.1097/MPA.0000000000001110.

PMID:
30028445
17.

Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma.

Kato Y, Yamada S, Suenaga M, Takami H, Niwa Y, Hayashi M, Iwata N, Kanda M, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Pancreas. 2018 Aug;47(7):823-829. doi: 10.1097/MPA.0000000000001105.

PMID:
29975352
18.

Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.

Tanaka N, Yamada S, Sonohara F, Suenaga M, Hayashi M, Takami H, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Sci Rep. 2018 Jun 29;8(1):9846. doi: 10.1038/s41598-018-28253-9.

19.

Pattern-Specific Transcriptomics Identifies ASGR2 as a Predictor of Hematogenous Recurrence of Gastric Cancer.

Tanaka H, Kanda M, Miwa T, Tanaka C, Kobayashi D, Umeda S, Shibata M, Suenaga M, Hattori N, Hayashi M, Iwata N, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Mol Cancer Res. 2018 Sep;16(9):1420-1429. doi: 10.1158/1541-7786.MCR-17-0467. Epub 2018 May 21.

PMID:
29784667
20.

A novel dual-marker expression panel for easy and accurate risk stratification of patients with gastric cancer.

Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Cancer Med. 2018 Jun;7(6):2463-2471. doi: 10.1002/cam4.1522. Epub 2018 May 7.

21.

Integrated multigene expression panel to prognosticate patients with gastric cancer.

Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Oncotarget. 2018 Apr 10;9(27):18775-18785. doi: 10.18632/oncotarget.24661. eCollection 2018 Apr 10.

22.

Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer.

Sawaki K, Kanda M, Miwa T, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2018 Jul;25(7):2083-2090. doi: 10.1245/s10434-018-6480-z. Epub 2018 Apr 16.

PMID:
29663169
23.

Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.

Ninomiya G, Yamada S, Hayashi M, Takeda S, Suenaga M, Takami H, Kanda M, Iwata N, Niwa Y, Tanaka C, Kobayashi D, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Oncol Rep. 2018 Jun;39(6):2664-2672. doi: 10.3892/or.2018.6349. Epub 2018 Apr 2.

PMID:
29620290
24.

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A.

Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9.

25.

Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study).

Asada T, Nakayama G, Tanaka C, Kobayashi D, Ezaka K, Hattori N, Kanda M, Yamada S, Koike M, Kodera Y.

Surg Today. 2018 Jun;48(6):609-617. doi: 10.1007/s00595-018-1634-y. Epub 2018 Feb 23.

PMID:
29476258
26.

PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma.

Kurimoto K, Hayashi M, Guerrero-Preston R, Koike M, Kanda M, Hirabayashi S, Tanabe H, Takano N, Iwata N, Niwa Y, Takami H, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Fujii T, Fujiwara M, Kodera Y.

Epigenetics. 2017;12(10):865-874. doi: 10.1080/15592294.2017.1365207. Epub 2017 Nov 27.

27.

Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society.

Yamada S, Fujii T, Takami H, Hayashi M, Iwata N, Kanda M, Tanaka C, Sugimoto H, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Surgery. 2017 Oct;162(4):784-791. doi: 10.1016/j.surg.2017.04.023. Epub 2017 Jun 24.

PMID:
28655416
28.

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).

Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y.

BMC Cancer. 2017 Apr 4;17(1):243. doi: 10.1186/s12885-017-3245-1.

29.

GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer.

Shimizu D, Kanda M, Tanaka H, Kobayashi D, Tanaka C, Hayashi M, Iwata N, Niwa Y, Takami H, Yamada S, Fujii T, Nakayama G, Fujiwara M, Kodera Y.

Sci Rep. 2017 Feb 6;7:42089. doi: 10.1038/srep42089.

30.

The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer.

Asano T, Yamada S, Fujii T, Yabusaki N, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Int J Surg. 2017 Mar;39:169-175. doi: 10.1016/j.ijsu.2017.01.115. Epub 2017 Feb 2.

31.

Stapling an extracorporeal Billroth-I anastomosis by the complete double stapling technique after laparoscopy-assisted distal gastrectomy.

Tanaka C, Fujiwara M, Kanda M, Murotani K, Iwata N, Hayashi M, Kobayashi D, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujii T, Kodera Y.

Asian J Endosc Surg. 2017 May;10(2):137-142. doi: 10.1111/ases.12357. Epub 2017 Jan 27.

PMID:
28127939
32.

Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.

Ninomiya G, Fujii T, Yamada S, Yabusaki N, Suzuki K, Iwata N, Kanda M, Hayashi M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Int J Surg. 2017 Mar;39:45-51. doi: 10.1016/j.ijsu.2017.01.075. Epub 2017 Jan 18.

33.

Prognostic relevance of SAMSN1 expression in gastric cancer.

Kanda M, Shimizu D, Sueoka S, Nomoto S, Oya H, Takami H, Ezaka K, Hashimoto R, Tanaka Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Oncol Lett. 2016 Dec;12(6):4708-4716. doi: 10.3892/ol.2016.5233. Epub 2016 Oct 6.

34.

The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.

Shimizu D, Kanda M, Sugimoto H, Shibata M, Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Int J Oncol. 2017 Feb;50(2):381-386. doi: 10.3892/ijo.2017.3833. Epub 2017 Jan 2.

35.
36.

Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer.

Nakayama G, Fujii T, Murotani K, Uehara K, Hattori N, Hayashi M, Tanaka C, Kobayashi D, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y.

Cancer Sci. 2016 Oct;107(10):1492-1498. doi: 10.1111/cas.13023.

37.

FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer.

Tanaka H, Kanda M, Shimizu D, Tanaka C, Kobayashi D, Hayashi M, Iwata N, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Niwa Y, Kodera Y.

Ann Surg Oncol. 2017 Oct;24(11):3438-3445. doi: 10.1245/s10434-016-5636-y. Epub 2016 Oct 21.

PMID:
27770343
38.

Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2-4 gastric cancer.

Tanaka Y, Kanda M, Tanaka C, Kobayashi D, Mizuno A, Iwata N, Hayashi M, Niwa Y, Takami H, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y.

Gastric Cancer. 2017 Jul;20(4):736-743. doi: 10.1007/s10120-016-0657-6. Epub 2016 Oct 12.

PMID:
27734274
39.

Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer.

Kanda M, Tanaka C, Kobayashi D, Tanaka H, Shimizu D, Shibata M, Takami H, Hayashi M, Iwata N, Niwa Y, Yamada S, Fujii T, Nakayama G, Fujiwara M, Kodera Y.

Int J Cancer. 2016 Nov 15;139(10):2290-8. doi: 10.1002/ijc.30286. Epub 2016 Aug 6.

40.

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.

Yabusaki N, Fujii T, Yamada S, Murotani K, Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Medicine (Baltimore). 2016 Jul;95(29):e4282. doi: 10.1097/MD.0000000000004282.

41.

Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer.

Kanda M, Shimizu D, Fujii T, Tanaka H, Tanaka Y, Ezaka K, Shibata M, Takami H, Hashimoto R, Sueoka S, Iwata N, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2016 Aug;23(Suppl 4):532-539. Epub 2016 Jun 30.

PMID:
27364510
42.

Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.

Kanda M, Shimizu D, Fujii T, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Int J Oncol. 2016 Sep;49(3):1195-202. doi: 10.3892/ijo.2016.3584. Epub 2016 Jun 17.

PMID:
27315569
43.

Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer.

Kanda M, Mizuno A, Tanaka C, Kobayashi D, Fujiwara M, Iwata N, Hayashi M, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Takami H, Niwa Y, Murotani K, Kodera Y.

Medicine (Baltimore). 2016 Jun;95(24):e3781. doi: 10.1097/MD.0000000000003781.

44.

Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection.

Yabusaki N, Fujii T, Yamada S, Suzuki K, Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Int J Surg. 2016 Jun;30:136-42. doi: 10.1016/j.ijsu.2016.04.049. Epub 2016 May 4.

45.

Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter.

Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Medicine (Baltimore). 2016 May;95(18):e3582. doi: 10.1097/MD.0000000000003582.

46.

S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.

Suenaga M, Yamada S, Fujii T, Tanaka C, Kanda M, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

J Surg Oncol. 2016 Mar;113(4):413-9. doi: 10.1002/jso.24147. Epub 2016 Jan 12.

PMID:
27100026
47.

Short-term outcomes after conventional transthoracic esophagectomy.

Niwa Y, Koike M, Hattori M, Iwata N, Takami H, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Nomoto S, Fujiwara M, Kodera Y.

Nagoya J Med Sci. 2016 Feb;78(1):69-78.

48.

NRAGE promotes the malignant phenotype of hepatocellular carcinoma.

Shimizu D, Kanda M, Sugimoto H, Sueoka S, Takami H, Ezaka K, Tanaka Y, Hashimoto R, Okamura Y, Iwata N, Tanaka C, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y.

Oncol Lett. 2016 Mar;11(3):1847-1854. Epub 2016 Jan 15.

49.

Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.

Kamiya T, Uehara K, Nakayama G, Ishigure K, Kobayashi S, Hiramatsu K, Nakayama H, Yamashita K, Sakamoto E, Tojima Y, Kawai S, Kodera Y, Nagino M; Nagoya Surgical Oncology Group and the Chubu Clinical Oncology Group.

Eur J Surg Oncol. 2016 Jun;42(6):829-35. doi: 10.1016/j.ejso.2016.02.014. Epub 2016 Feb 27.

PMID:
26968228
50.

Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer.

Kanda M, Shimizu D, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Oncotarget. 2016 Mar 22;7(12):13667-79. doi: 10.18632/oncotarget.7269.

Supplemental Content

Loading ...
Support Center